Company Information
CIN
Status
Date of Incorporation
15 July 1972
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
07 August 2023
Paid Up Capital
1,692,227,200
Authorised Capital
2,350,000,000
Directors
Nikhil Khattau Nirvan
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Ameera Sushil Shah
Director/Designated Partner
over 2 years ago
over 2 years ago
Haigreve Khaitan
Director/Designated Partner
over 2 years ago
over 2 years ago
Manish Mahendra Choksi
Director/Designated Partner
over 2 years ago
over 2 years ago
Samir Uttamlal Mehta
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Shailesh Vishnubhai Haribhakti
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Aman Samir Mehta
Director/Designated Partner
over 3 years ago
over 3 years ago
Maurice Antoine Rene Chagnaud
Director/Designated Partner
over 3 years ago
over 3 years ago
Jinesh Dushyant Shah
Director/Designated Partner
over 6 years ago
over 6 years ago
Nayantara Bali
Director/Designated Partner
almost 7 years ago
almost 7 years ago
Sudhir Menon
Director/Designated Partner
over 7 years ago
over 7 years ago
Renu Challu
Director
over 10 years ago
over 10 years ago
Pradeep Kumar Bhargava
Director
over 12 years ago
over 12 years ago
Renu Sud Karnad
Director
over 14 years ago
over 14 years ago
Sanjaybhai Srenikbhai Lalbhai
Director
almost 23 years ago
almost 23 years ago
Sudhir Uttamlal Mehta
Beneficial Owner
over 43 years ago
over 43 years ago
Past Directors
Maheshkumar Agrawal
Nodal Officer
over 6 years ago
over 6 years ago
Ashish Nanda
Director
over 11 years ago
over 11 years ago
Ashok Saligram Modi
Cfo(kmp)
over 11 years ago
over 11 years ago
Chaitanya Mavinkurve Dutt
Whole Time Director
almost 14 years ago
almost 14 years ago
Leena Srivastava
Director
about 14 years ago
about 14 years ago
Ramnarayan Subramaniam
Director
about 21 years ago
about 21 years ago
Shashikant Harilal Bhojani
Director
over 24 years ago
over 24 years ago
Kiran Sharadchandra Karnik
Director
almost 25 years ago
almost 25 years ago
Markand Induprasad Bhatt
Director
about 25 years ago
about 25 years ago
Patents
Present invention relates to a thermostable, alcohol free foamable pharmaceutical composition comprising minoxidil in combination with aminexil and one or more pharmaceutically acceptable excipients comprising atleast one C4-C6 glycol and one or more pharmaceutically acceptable surfactant. Present invention also rel...
The present invention relates to novel pyridinium compounds their isomers steroisomers atropisomers conformers tautomers polymorphs hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to th...
The present invention discloses a process for the production of sertraline hydrochloride Form-V comprising the steps of (a) dissolving or suspending sertraline mandelate in a protic solvent or a mixture of protic solvents ; (b) reducing the pH of the solution or the suspension by adding hydrochloric acid in a solven...
Injectable dosage form(s) of lamotrigine or a pharmaceutically acceptable salts thereof for immediate and/or prolonged release; and process of preparing the said injectable dosage form(s).
The present invention relates to a process for preparing a modified release pharmaceutical composition of valproic acid and/or pharmaceutically acceptable salt thereof, with pharmaceutically acceptable excipients.
The present invention relates to solid oral pharmaceutical compositions comprising aspirin and citric acid, and process of preparation of such compositions.
A modified release dosage form comprising of a highly soluble salt of HMG-CoA reductase inhibitor fluvastatin, which utilizes dual retard technique to effectively reduce the quantitiy of release controlling agents; a process for preparing the dosage form.
A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.
The present invention relates to L-valine benzyl ester salt of statin or sartan, a process for preparation thereof and an intermediate compound L-valine benzyl ester salt of statin or sartan, useful in the synthesis of purified statin or sartan and its salts. Particularly, the present invention relates to l-valine b...
The present invention relates to novel fused Imidazobenzothiazole derivatives their pharmaceutically acceptable salts and their isomers steroisomers atropisomers conformers tautomers polymorphs hydrates solvates and N oxide. The present invention also encompasses pharmaceutically acceptable compositions of said comp...
The invention relates to sustained release pharmaceutical compositions of venlafaxine, process for preparing such compositions and method of using such compositions. Preferably, it relates to a sustained release pharmaceutical composition of venlafaxine comprising a first sustained release portion and a second susta...
A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is equal to or more than 1:20 and the weight of modified release ac...
Disclosed is an acid addition salt of donepezil wherein acid counterion is selected from the group consisting of pamoic acid cypionic acid camphor sulfonic acid enanthic acid fusidic acid gluceptic acid gluconic acid lactobionic acid lauric acid valeric acid Dibenzoyl D Tartaric acid and terephthalic acid. Disclosed...
The present invention relates to stable pharmaceutical compositions atorvastatin and amlodipine, and process for preparation thereof.
TITLE: NOVEL COMPOUNDS FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND COMPOSITION COMPRISING THEM.
The invention disclose novel compounds of the pyridinium series useful for the managment of diabetes and aging-related vascular complilcations, includin...
The present invention relates to an improved process for the preparation of flibanserin and its intermediates.
The present invention relates to a pharmaceutical composition of tapentadol for nasal administration. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for nasal administration and its use in the treatment of pain.
The present invention provides a stable solid oral pharmaceutical composition comprising brexpiprazole, a binder and a stabilizer, and a process for the preparation of said pharmaceutical composition. The present invention also relates to a pharmaceutical preparation which contains brexpiprazole having excellent sto...
The present invention relates to a solid oral dosage form comprising (a) Rivaroxaban and (b) inert granules comprising a hydrophilic polymer, and one or more pharmaceutically acceptable excipient(s), wherein said inert granules are free of Rivaroxaban. The present invention also relates to a solid oral dosage form c...
The present invention relates to a stable pharmaceutical composition comprising prasugrel and aspirin, and process for the preparation of said composition.
Present invention relates to solid oral pharmaceutical composition prepared by a process comprising granulation of the mixture comprising sugar alcohol and colorant by a granulating solution comprising thyroxine active drug, alkalizer and alcoholic solvent.
The present invention relates to an improved process for the statin or salts of statins cleavage of A1 and/or A2 alcohol or 1, 3-diol protecting groups of formula II using potassium hydrogen sulphate.
The present invention relates to novel substituted imidazo[1 2 a]pyrimidine compounds of formula (I) their pharmaceutically acceptable salts and their isomers stereoisomers conformers tautomers polymorphs hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said c...
The present invention relates to a method for producing a 1,2-dihydropyridine-2-one compound of formula (I) comprises reacting a compound of formula (II) with a boronic acid derivative of formula (III) in the presence of a palladium compound, a phosphorus compound, a cesium compound and/or a base. The present invent...
The present invention relates to process of preparation milnacipran and salts thereof. The process involved for the preparation of milnacipran and salt thereof is cost effective, commercially viable and industrially feasible. Further salt of compound of milnacipran obtained by this process is having higher yield and...
The present invention relates to a novel process for the preparation of Rivaroxaban of formula (I) and its pharmaceutically acceptable salts. The present invention also relates to novel intermediates, 5-(azidomethyl)-3-[4-(3-oxotetrahydro-2H-pyran-4-yl)phenyl]-1,3-oxazolidin-2-one of formula (VI) and its enantiomeri...
The present invention provides a process for the preparation of Vilazodone of formula (I) or its pharmaceutically acceptable salts comprises amidation of the Ethyl-5-{4-[4-(5-cyano-3-indolyl)butyl]-l-piperazinyl} benzofuran-2-carboxylate of formula (II). The present invention also relates to an improved process for ...
Present invention relates to a stabilized composition of Ibrutinib in an amorphous form, comprising ibrutinib, a hydrophilic polymer selected from hydroxypropylmethylcellulose, polyvinylpyrrolidone and hydroxypropylcellulose, and a carrier selected from silicon dioxide and magnesium aluminometasilicate and one or mo...
The present invention relates to pharmaceutical co-crystals of Febuxostat, Pharmaceutical composition thereof, processes for their preparation and their use for the chronic management of hyperuricemia in patients with gout.
The present invention relates to stable extended release formulation comprising Pramipexol or a pharmaceutically acceptable salt thereof in a matrix comprising at least one neutral polymer with Dicalcium phosphate and further cxcipients, wherein the resulting extended release formulation provides pH-dependent releas...
The present invention relates to pharmaceutical compositions comprising repaglinide and metformin.
The present invention relates to l-(diphenylmethyl) piperazine salt of rosuvastatin, a process for preparation thereof and novel intermediate compound i.e. 1-(diphenylmethyl) piperazine salt of rosuvastatin, useful in the synthesis of purified rosuvastatin and its salts.
Present invention relates to multiparticulate pharmaceutical composition having first inert component comprising one or more pharmaceutical excipients and at least one subsequent component comprising roflumilast wherein said first inert component is free of roflumilast. Invention also relates to process of preparati...
The present invention relates to a controlled release pharmaceutical composition comprising a single particle population comprising fluvoxamine or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.
Present invention relates to a non-emulsified, alcohol free foamable composition comprising clindamycin or pharmaceutically acceptable salt thereof, at least one permeation enhancer and one or more pharmaceutically acceptable carriers. The non-emulsified alcohol free foamable composition of present invention remains...
This invention relates to pharmaceutical formulations comprising 1 (2 thien 2 yl 2 oxo ethyl) 3 (methanesulfonyl hydrazine carbonyl) pyridinium its pharmaceutically acceptable salts salt cocrystals and co crystals particularly 1 (2 thien 2 yl 2 oxo ethyl) 3 5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. ...
An improved dissolution apparatus of USP type I is disclosed. Disclosed dissolution apparatus incorporates additional stirring means that are attached at basket bottom. Additional stirring means provide better hydrodynamics in media contained in container of the apparatus, especially in lower zone of the container b...
The present invention relates to a novel long acting pharmaceutical composition of rasagiline or its pharmaceutically acceptable salts or its ion pair complex to provide prolong release of rasagiline for extended period of time. The present invention also provides a process for the preparation and use of the said co...
The present invention relates to a pharmaceutical composition of tapentadol for parenteral administration which provides prolonged release of tapentadol. Present invention also relates to the process of preparation of pharmaceutical composition of tapentadol for parenteral administration and its use in the treatment...
The present invention relates to an improved process for the preparation of olmesartan medoxomil and 4-(1-hydroxy-1 -methylethyl)-2-propyl-1 H-imidazole-5-carboxylic acid ethyl ester, the key intermediate for the preparation of olmesartan medoxomil.
The present invention relates to novel l-(mercaptomethyl)-cyclopropane acetic acid Benzhydryl piperazine salts of formula (II) and process for the preparation thereof. Furthermore, the invention relates to the use of novel l-(mercaptomethyl)-cyclopropane acetic acid Benzhydryl piperazine salts of formula (II) for th...
Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9- tetrahydro-4H,5H-10-thia-l,4a-diaza-benzo[a]azulene-3-carbonyl)-aminoj-acetic acid (compound A) in the range of 2.5 mg to 60 mg. Present invention ...
The present invention relates to a novel acid addition salt of risperidone wherein acid counterion is selected from the group consisting of pamoic acid caproic acid cypionic acid decanoic acid camphor sulfonic acid enanthic acid palmitic acid fusidic acid gluceptic acid gluconic acid lactobionic acid lauric acid lev...
The present invention relates to an improved process for the preparation of Dronedarone or its pharmaceutically acceptable salts having reduced content of I-chloro-3(di-n-butylamino) propane (VI). The process comprises reduction of 2-butyl-3-(4-(3-di-n-butylamino-propoxy) benzoyl)-5-nitro-1-benzofuran (II) to 5-amin...
A ready to use stable sustained release oral liquid suspension dosage form of pharmaceutical active ingredients which is easy to administer and particularly beneficial for the pediatric and geriatric patients. The suspension dosage form comprises sustained release pellets comprising inert pellets surrounded by seal ...
The present invention relates to salt of (5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinylphenyl)-1 3-oxazolidin-2-one. The invention further relates to process of its preparation and its use in synthesis of Linezolid. Further (5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinylphenyl)-1, 3-oxazolidin-2-one salt is obtained ...
The present invention relates to particulate mitiglinide calcium wherein at least 90% of the particles, by volume, having particle size in the range of about 50 microns to about 300 microns and a process for the preparation thereof. The present invention also relates to a process for the preparation of crystalline m...
The invention relates to Benzhydryl piperazine salts of [R-(E)]-l-[[[l-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(l-hydroxy-l-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid. Furthermore, the invention relates to the use of Benzhydryl piperazine salts of [R-(E)]-l-[[[l-[3-[2-(7-chloro-2-q...
The present invention relates to an improved process for preparing 3-(3-trifluoromethylphenyl) propanal (III), which is the key intermediates for the preparation of cinacalcet and its pharmaceutically acceptable salts and solvates, as well as the use of compound of formula (III) prepared by instant process for the p...
The present invention relates to a new class of heterocyclic compounds and pharmaceutically acceptable salts thereof, process for preparing the same, pharmaceutical composition containing these compounds and to their use in treatment of diseases caused due to formation and accumulation of AGEs (Advanced Glycation en...
The present invention provides a pharmaceutical composition capable of forming in situ implant comprising goserelin or its pharmaceutically acceptable salts thereof biodegradable polymer and a biocompatible organic solvent wherein the biocompatible organic solvent is miscible to dispersible in aqueous medium or body...
The present invention relates to pharmaceutical compositions of montelukast. More particularly, the present invention relates to pharmaceutical compositions of montelukast comprising less than 1.6 % by weight of an organoleptic additive.
The invention relates to controlled release pharmaceutical compositions of tolterodine, and process for preparing such compositions.
The present invention relates to an improved process for the preparation of substantially pure clopidogrel bisulphate Form I.
This invention relates to a water dispersible formulation of an active pharmaceutical ingredient or pharmaceutically acceptable slat hereof and one or more adjuvants without the use of swellable clay. More particularly, the invention comprises a dispersible formulation of anti-epileptic drug - lamotrigine. This inve...
The present invention discloses a process for the preparation of pharmaceutical composition in the form of controlled release once a day formulation comprising an active ingredient such as ciprofloxacin (78-84% w/w); an in-situ gas forming agent (5-10% w/w); a swellable polymer selected from hydroxypropyl methyl cel...
A modified release dosage form comprising of a highly soluble salt of HMG-CoA reductase inhibitor fluvastatin which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form. Also the active ingredient can be low solubility active ingredi...
The present invention relates to stable pharmaceutical compositions of HMG-CoA reductase inhibitor and process for preparation thereof. More particularly, it relates to pharmaceutical compositions of HMG-CoA reductase inhibitor comprising of polyethylene glycol (PEG), one or more alkalizing agents, and pharmaceutica...
The present invention relates to sustained release pharmaceutical compositions of
darifenacin; and process for preparing such compositions. More particularly, it relates
to gastro-retentive compositions comprising (i)darifenacin and (ii) a matrixcomprising at least one swellable polymer, wherein the composition ...
Specialized controlled release oral dosage form(s) for pH dependent solubility active ingredients, which reduces the effect of different pH of various portions of gastrointestinal tract on drug release from the dosage form, wherein the active ingredient does not have absorption window in the proximal part of the gas...
The present invention relates to topical dosage form(s) of lamotrigine or its pharmaceutically acceptable salts thereof for prolonged release; and process of preparing the said topical dosage form(s).
The present invention relates to an improved process for the manufacture of 2-(2-Nitroanilino)-5-methylthiophene-3-carbonitrile of formula (II) comprising the reaction of 2-amino-5-methylthiophene-3-carbonitrile (III) & 2-fluoronitrobenzene (IV) in a solvent and in the presence of a cosolvent and a base without any ...
The present invention provides an improved process for the synthesis of nebivolol or its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula (l). The present invention further provides a new Form T1 of nebivolol and its pharmaceutically acceptable salts.
The present invention also pro...
The instant invention relates to a gastroretentive sustained release dosage form of Alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, which gives predictable drug release over an extended period of time. Gastric retention of the present invention is ensured by size of the table...
This invention relates to a new crystalline form of ethyl 4-(1-hydroxymethylethyl)-2-propyl-1 -[2"-(N-triphenylmethyltetrazol-5-yl)-4-biphenylmethyl] imidazol-5-yl carboxylate and its use for the preparation of olmesartan medoxomil. This present invention also relates to crystalline potassium salt of 4-(1-hydroxymet...
TITLE: THIAXOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYLPEPTIDAR INHIBITORS.
The invention discloses a novel series of compound represented by genral formula(I), its derivatives analogs, tautomeric forms,stereoisomers, polymorphs, pharmaceutically acceptable salts, solvates wherein X,n,k,z...
The present invention relates to sustained release pharmaceutical formulation of Venlafaxine, which gives predictable drug release over an extended period of time. Extended release of the present invention is ensured using release controlling triglyceride. Further, present invention also relates to a process for pre...
The invention relates to a stable solid oral tablet dosage form comprising of donepezil hydrochloride form - I and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75 : 25) as a diluent, and with a direct ...
The present invention relates to an improved process for the preparation of Bosentan. In particular it relates to a process for preparing Bosentan comprising the reaction of sulfonamide intermediate of formula (II) with ethylene glycol in the presence of organic base. The invention also relates to a pharmaceutical c...
The present invention relates to novel compounds of general formula (I), or
pharmaceutically acceptable salt thereof, wherein the substituents in formula ([) have the
meanings as defined in the description that follows.
The present invention also relates to a process for the preparation of the said novel
compoun...
The present invention relates to rapidly dissolving pharmaceutical compositions of pioglitazone and process for preparing such compositions. More particularly, it relates to rapidly dissolving pharmaceutical compositions comprising pioglitazone and hydroxypropylcellulose comprising a molecular weight ranging from 70...
The present invention relates to a stable, solid oral pharmaceutical composition of sildenafil manufactured by nonaqueous granulation. It also relates to the process involved therein.
An improved, novel and simple industrial process for the preparation of Donepezil of formula (I) and its pharmaceutically acceptable salts manufactured by the condensation of 5,6-dimethoxy indanone of formula (III) with 1- benzyl-4-piperidine carboxaldehyde of formula (IV) to give l-benzyl-4-[(5,6-dimethoxy-l-i...
The present invention relates to a pharmaceutical composition of practically water insoluble or low water soluble compounds containing catechol moiety by enhancing the solubility of such compounds using one or more alkalising agent and optionally adding one or more pharmaceutically acceptable excipient. The present ...
The present invention relates to prevention of alcohol induced dose dumping in modified release pharmaceutical compositions intended for oral administration.
The present invention relate to process of manufacturing pharmaceutical composition comprising active substance valsartan, optionally in combination with another active ingredient, preferably diuretic such as hydrochlorothiazide (HCTZ), in the form of a solid oral dosage form by wet granulation, wherein the said com...
The present invention relates to prolonged release oral dosage form comprising amisulpride, preferably in the form of a multiunit pellets or micro tablets filled into capsule or bilayered tablet.
It also relates to the process for preparing the said dosage form.
The present invention describes improved and industrially viable process for the preparation of Rimonabant and also discloses Rimonabant in the solid state and, more particularly, to crystalline solvates and amorphous forms of Rimonabant having unique physical properties and process for the preparation thereof. The ...
The invention provides a nov el process for the preparation of substantially pure amorphous Lercanidipine hydrochloride directly from the lercanidipine base without having any intermediary stage of the production of crystalline lercanidipine hydrochloride, which provides better yield of production, and pharmaceutica...
The present invention relates to a taste-masked rapidly disintegrating pharmaceutical composition of racecadotril; process for preparing such composition and a method of using such composition.
The present invention is directed to controlled release dosage form of Gliclazide, exhibiting pH independent release profile over a wide range, having one or more release controlling polymer and free from additional saccharide component and process for preparing such dosage form.
The present invention relates to sustained release pharmaceutical compositions of alfuzosin, a rate-controlling polymer and optionally one or more pharmaceutically acceptable excipients. process for the preparing such compositions and method of using the compositions.
The present invention relates to an enantioselective process for the preparation of trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-lH-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole-l-one with an improved yield and quality. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-lH-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole-l-one is useful int...
The invention relates to improved processes for preparing 3-aryloxy-3-arylpropylamines, intermediates or salts thereof having a substantially high purity. The invention also relates to a method for the preparation of Duloxetine HCl. The present invention also relates to a method for the purification of duloxetine hy...
The present invention relates to stable solid oral dosage form of lercanidipine by using a process of preparation of adsorbates. The invention further relates to lercanidipine adsorbates that are obtainable by said process, as well as pharmaceutical formulations prepared while employing said lercanidipine adsorbates...
A novel modified release dosage form comprising of a high solubility active ingredient,wich utilizes dual retard technique to effectively reduce the quantity of release controlling agents;a process for preparing the dosage form.
A PROCESS FOR THE PREPARATION OF MULTIPARTICULATE CONTROLLED RELEASE FORMULATION OF LAMOTRIGINE
The invention discloses an improved process for the purification of ropinirole hydrochloride by dissolving or suspending crude ropinirole base or its pharmaceutically acceptable salt in a suitable solvent, reacting with a nitrogenous base to form an imine derivative, optionally treating the reaction mixture with a ...
This invention relates to a water dispersible formulation of an active pharmaceutical ingredient or pharmaceutically acceptable slat hereof and one or more adjuvants without the use of swellable clay. More particularly, the invention comprises a dispersible formulation of anti-epileptic drug-lamotrigine. This invent...
The present invention relates an improved process for the preparation of Paliperidone.
The present invention relates to sustained release pharmaceutical composition of quetiapine, and process for preparing such composition. More particularly, it relates to sustained release pharmaceutical composition of quetiapine comprising carrageenan and pharmaceutically acceptable excipients.
...
The present invention describes two new polymers of (4R-Cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-di-methyl-[1,3]-dioxane-4-yl-acetic acid tertiary butyl ester and the process for their preparation. This invention also relates to the use of these two polymor...
The present invention relates to a process for the preparation of 2-Acetoxy-5-(α-cycloprpylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine & pharmaceutically acceptable salt thereof comprising the use of 2-acetoxy-tetrahydrothienopyridine derivatives or salt thereof. The present invention also relat...
The present invention relates to a stable pharmaceutical composition of amiodipine and valsartan and a process for preparation thereof.
The present invention relates to a process for preparing Cinacalcet hydrochloride (I) comprising (a) providing a solution of free base of cinacalcet in a solvent selected from a sulfolane, ethylene glycol or dimethoxyethane, and mixtures thereof; (b) treating said solution with hydrochloric acid to obtain a reaction...
The present invention relates to extended release solid oral pharmaceutical composition of paliperidone comprising atleast one hydrophillic release controlling agent and/or atleast one water insoluble release controlling agent and optionally atleast one wetting agent.
The present invention also relates to a process...
The present invention relates to pharmaceutical compositions of escitalopram. More particularly, the present invention relates to a pharmaceutical composition comprising escitalopram particles having a specific particle size distribution; and process for preparing such composition.
The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and ...
The present invention relates to a stable pharmaceutical composition of levetiracetam and process for preparation thereof.
The present invention relates to sustained release pharmaceutical compositions of ranolazine; and process for preparing such compositions.
The present invention relates to a solid oral dosage form comprising a combination of metformin and micronized glibenclamide.
The invention relates to an improved process for the preparation of solifenacin base (1). The process involves the use of a phase transfer catalyst and/or mixture of toluene and sulfolane as solvent for the preparation of solifenacin base via the condensation reaction between alkyl 1(S)-phenyl-1,2,3,4-tetrahydroisoq...
The present invention relates to solid oral pharmaceutical composition of duloxetine, process for preparing such composition and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an...
The invention relates to a novel taste masked oral pharmaceutical compositions comprising racecadotril, more particularly dry powder for suspension comprising racecadotril using ion exchange resin and the process for preparing the same.
The present invention relates to solid oral sustained release tablet dosage form of indapamide by wet granulation, comprising high viscosity hydroxypropyl methylcellulose alone as release controlling agent, further the said composition is free from povidone or copovidone or combination of release controlling agents....
The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z ale as defined in the specification, method for its preparation, composition cortaining such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significant...
The present invention relates to an efficient process for the purification of pharmaceutically active piperidine-1-yl-benzisoxazole derivative i.e. l-[4-[3-[4-(6-fluoro-l,2-benzisoxazol-3-yl)-1-piperidinyl] propoxy]-3-methoxyphenyl]ethanone i.e. Iloperidone of formula (I) comprising: a) providing a solution of Ilope...
A dosage form comprising of a high dose, high solubility antidiabetic active ingredient as modified release and a low dose antidiabetic active ingredient/as immediate release where the weight ratio of immediate release antidiabetic active ingredient and modified release antidiabetic active ingredient is equal to or ...
The present invention relates to an improved process for the preparation lamotrigine. An improved process for the preparation of lamotrigine comprises cross coupling reaction of 2,3-dichloro-phenylboronic acid with 6-bromo-3,5-diamino triazine in the presence of palladium catalysts and appropriate base.
...
The present invention relates to new, improved and industrially viable process for the preparation of Lercanidipine or its pharmaceutically acceptable salts using novel derivatives of 2,N-dimethyl-N-(3,3-diphenylpropyl)-1-amino compounds and novel polymorphs of Lercanidipine hydrochloride, its process of preparation...
The present invention relates to orally disintegrating tablet dosage form of Rizatriptan manufactured by direct copression. Its also realtes to the process involved therein.
This invention relates to an improved process for the preparation of solifenacin succinate. This invention also relates to a process for the recovery and reusability of 3(R)-quinuclidinol and 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline.
The present invention relates to a pharmaceutical composition comprising telmisartan and hydrochlorothiazide; and process for preparation of such composition.
The present invention relates to a pharmaceutical composition comprising telmisartan and amlodipine components in dissolving matrix and process for preparation of said composition.
This invention discloses novel compounds of benzofuroxan series and to their use in therapeutics. In particular the invention concerns novel benzofuroxan derivatives, pharmaceutical compositions containing these compounds, and their use as tolerance resistant nitric oxide donors in treatment of angina pectoris. In ...
The present invention contemplates to a pharmaceutical composition of fidarestat exhibiting improved dissolution profile and enhanced bioavailability. Invention also relates to the process for preparing such composition of fidarestat.
The present invention relates to an improved process fof the preparation of l-[2-amino-l-(4-methoxyphenyl)ethylJcyclohexanol(V), comprising reducing l-[cyano-(4-methoxyphenyl) methyljcyclohexanol of formula (IV ) in a solvent in presence of a Sodium borohydride and Iron salts which is suitable for bulk production. P...
The present invention relates to novel intermediate 1-(2,6-difluorobenzyI)-4-(4,4-dimethyl-4,5-dihydro-1,3-oxazole-2-yl)-lH-l,2,3-triazole of formula (V) and its process for preparation. The present invention further comprises a novel intermediate of formula (VI) and its process of preparation. The invention also re...
In one embodiment, the present invention relates to a pharmaceutical composition comprising: (a) compound of formula (I) or (II) as defined above or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of an antihypertensive agent, an antidiabetic agent, a...
NO ABSTRACT
A dosage form comprising of an active ingredient as modified release and an active ingredient as immediate release. Wherein the modified release active ingredient is selected from high dose, low solubility active ingredients or low dose, high solubility active ingredients and the immediate release active ingredient ...
The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agent...
This invention relates to an improved process for the preparation crystalline Form I of atorvastatin hemi-calcium.
The present invention relates to an improved process for the preparation of 1,7"-dimethyl-2"-propyl-2,5"-bi-lH-benzimidazole which is the key intermediate for the preparation of Telmisartan and its pharmaceutically acceptable salts.
This invention relates to an improved process for the preparation of microparticles of nucleophilic compounds. The process is free from the use of benzyl alcohol as a solvent, which eliminates the need of intermediate drying and eventually reduce the residual solvent. The process also describes the use of aprotic so...
The present invention relates to a pharmaceutical composition for oral administration which comprises a benzofuran derivative or one of the pharmaceutically acceptable salts thereof, as an active principle, and cyclodextrin or its derivative, optionally in combination with one or more pharmaceutical excipient. Prese...
The present invention relates to prolonged release oral dosage form comprising levosulpiride, preferably in the form of a multiunit pellets or micro tablets filled into capsule or bilayered tablet.
It also relates to the process for preparing the said dosage form.
The present invention relates to novel compounds, their pharmaceutically acceptable salts,
and their isomers, steroisomers, conformers, tautomers, polymorphs, hydrates and solvates.
The present invention also encompasses pharmaceutically acceptable compositions of said
compounds and process for preparing novel co...
The present invention relates to the isolated N-alkylated lercanidipine hydrochloride impurity, processes for the preparation thereof and the use of N-alkylated lercanidipine impurity as a reference marker. The present invention also discloses process for the preparation of substantially pure Lercanidipine hydrochlo...
Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance and process of preparing the formulations. It provides better control of blood plasma levels than conventional tablet formulations that is administered onc...
The present invention relates to stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability. In the another Pharmaceutical composition of the present invention rabeprazole or its enentiomers or its pharmaceutically acceptable salt are combined with one or more prokinetic agent(...
A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified rele...
The present invention encompasses the novel substituted heterocyclic compounds
represented by formula (I) or their pharmaceutically acceptable salts, wherein the
substituents in formula (I) have the meanings as defined in the specification.
The invention also encompasses process for preparing such compound, pharm...
The present invention relates to stabilized pharaceutical compositions of clopidogrel mesylate, which is highly hygroscopic, unstable salt and the process for preparing such compositions
Present invention relates to a stable pharmaceutical composition comprising intimate mixture of alogliptin and metformin and suitable pharmaceutically acceptable excipient/s; wherein metformin is present in about 3.3 parts or more parts by weight relative to 100 parts by weight of the total weight of part comprising...
Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent,the proton pump inhibitor is as delayed release and the pokinetic agent is as sustained release,having improved patient compliance and process of preparing the pharmaceutical compositions.
...
The present invention relates to pharmaceutical composition comprising active substance valsartan, optionally in combination with another active ingredient, preferably diuretic such as, hydrochlorothiazide (HCTZ), in the form of a tablet or capsule manufactured by melt granulation. Further, present invention also re...
A container adapted for storage and transport of product. The container comprises plurality of boxes, made of insulating material wherein inner box houses the product and coolant pads and is further wrapped or laminated with heat resistant material, and is placed in an outer box containing coolant pads.
...
Present invention relates to a stable solid oral composition comprising (a) Ivabradine or pharmaceutically acceptable salt thereof, optionally one or more pharmaceutical excipient(s) and (b) inert granules comprising one or more diluent, one or more cellulosic binder and optionally one or more pharmaceutical excipie...
A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active i...
The present invention relates to amorphous darifencain hydrochloride, its preparation and its use for the preparation of darifenacin hydrobromide. The present invention also relates to the process for the preparation of intermediate used for the preparation of darifencain hydrobromide.
(3 SEP2009
...
The present invention relates to a stable pharmaceutical composition comprising febuxostat and one or more of the component selected from acidic co-formers, polymers, and amino acids, processes for their preparation and their use for the chronic management of hyperuricemia in patients with gout.
...
Present invention relates to a new package specially for moisture-sensitive products, that includes a desiccated induction sealable wad suitable for both closed and in-use stability conditions. The present invention also relates to induction sealable wad, where the desiccant materials is a part of the wad to absorb ...
The present invention relates to a stable solid oral composition comprising (a) dapagliflozin, optionally one or more pharmaceutical excipient(s) and (b) inert granules comprising one or more diluent(s), one or more binder(s) and optionally one or more pharmaceutical excipient(s), wherein said inert granules are sub...
ABSTRACT
LOW DOSE PHARMACEUTICAL COMPOSITION
Present invention relates to a low dose pharmaceutical composition, preferably oral composition comprising therapeutically effective amount of [(2-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H,5H-10-thia-l,4a-diaza-benzo[a]azulene-3-carbonyl)-amino]-acetic acid (compound A) i...
The present invention relates to novel compounds of 2-propene-l-one series, of general formula (I), tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable solvates and
pharmaceutically acceptable compositions containing them, wherein R5, R6, Q and Y are as defin...
The present application relates to p38 MAPK inhibiting indanyl urea derivatives and its process of preparation pharmaceutical composition and use for the preparation of medicament for treatment of inflammatory diseases such as airway diseases.
The invention is for an improved process for of production of risperidone of formula (I) which comprises the steps of: (a) reacting a halo compound with an oxime in a solvent and a base at 10-40°C; (b) refluxing the reaction mixture of step (a) for 4- 10 hours; (c) adding base to the cooled refluxed mixtu...
The invention discloses a process for the preparation of 1-[2-(dimethylamino)-1-(4-methoxyphenyl) ethyl] cyclohexanol (I), Venlafaxine and itspharmaceutically acceptable salts, which comprises the steps of(a)condensing 4-methoxy phenyl acetonitrile (II) with cyclohexanone (III) ...
The invention discloses process for the preparation of 2H-1-benzopyran-2-methanol, a, a' [iminobis(methylene)]bis[6-fluoro-3,4-dihydro-,[2R*[R*(S*)]]]] i.e. nebivolol lof formula (IX) or its pharmaceutically acceptable saltscomprising the steps of:(a) reacting 6-fluoro-3,4-dihydro-2H-1-benzopyra...
The invention discloses a compound represented by formula (I) and its pharmaceutically or cosmetically acceptable saltswherein A, B, R1, R2, R3, R4, R5 and X and Y are as defined in the specification, process for their and also pharmaceutical and cosmetic compositions comprising them. ...
The present invention discloses for a process for preparation of a controlled release formulation for water soluble drugs comprising, a water soluble active pharmaceutical ingredient, a polysaccharide gum, a lipophilic ingredient, an inert carrier and pharmaceutically acceptable excipients, diluents and addi...
The invention discloses an improved process for the preparation of (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenylcarbamate hydrogen (2R,3R)-tartarate, i.e.rivastigmine hydrogen tartarate.
The invention discloses a novel series of compoundrepresented by general formula (I), its derivatives, analogs,tautomeric forms, stereoisomers, polymorphs, pharmaceuticallyacceptable salts, solvates wherein X, n, k, z, R1, R2, R3, R4, R5and R6 are as defined in the specification that ...
A doges from comprising of a high dos, high solubility antidiabtic active ingredient as modified relases and a low does ntidiabetic active ingredient as immdiate release where the weight ratio of immediate release antidiabetic active ingredient and modified release antidiabetic active ingredient is equal to ...
A process for the preparation of once a day orally administered pharmaceuticalcomposition, wherein the unit dosage form is prepared by following steps :i) preparing proton pump inhibitor part using the steps:a) by drug layering process on seeds to form core OR preparing granules comprising ...
The invention discloses a process for separating a racernic mixture, or an optically enriched mixture of a chiral amine by an optically pure compound of formula (I), wherein R1, R2, R3 and R4 are as defined in the specification.
ABSTRACT
PROCESS FOR THE PREPARATION AND PURIFICATION OF
EMPAGLIFLOZIN INTERMEDIATES
The present invention relates to a process for the preparation 5 of 1-chloro-4-
(1-methoxy-D-glucopyranos-1-yl)-2-(4-(S)-tetrahydrofuran-3-yloxy-benzyl)
benzene of Formula II and its use for the preparation of empagliflozin. Th...
Embodiments of the present disclosure relate to dissolution apparatus of certain types that employ a “stirring means” attached to a shaft to achieve desired agitating action.In an aspect, the “stirring means” can be one or more baffles or paddles that incorporatemesh/screen/lattice/web like structure mainly to readi...
The present invention relates to salts of sacubitril and their use for the preparation of amorphous trisodium sacubitril valsartan. In particular, the present invention relates to benzhydril piperazine salts of sacubitril and a polymorph of L-lysine salt of sacubitril, and their use for the preparation of amorphous ...
The present invention relates to a novel process for preparing a stable solid oral composition containing Tenofovir disoproxil fumarate, Emtricitabine and Rilpivirine hydrochloride; wherein Tenofovir disoproxil fumarate and Rilpivirine hydrochloride are not physically separated in composition.
The present invention relates to solid lipid nanoparticles of tapentadol, pharmaceutical composition comprising said solid lipid nanoparticles and process of preparation thereof. Particularly present invention relates to in-situ gel composition comprising solid lipid nanoparticles of tapentadol for nasal administrat...
Present invention relates to a pharmaceutical composition comprising apremilast in an amorphous form, ethyl cellulose and one or more pharmaceutically acceptable excipient(s). Invention also relates to process for preparation of said pharmaceutical composition and its use in the treatment of severe plaque psoriasis ...
The present invention provides a stable sustained release solid oral dosage formulation of topiramate which comprises single population of sustained release pellets, preferably pellets, which includes polyvinyl acetate polymer or derivative thereof as atleast one of sustained release material and is free from alkali...
The present invention relates to isolated intermediates of SGLT2 inhibitors, process for their preparation, and processes for the preparation of SGLT2 inhibitors. In particular, the present invention relates to isolated intermediate of dapagliflozin, isolated intermediates of empagliflozin, and process for their pre...
Present invention relates to a stable pharmaceutical composition comprising Dasatinib propylene glycol solvate, hydroxyl propyl cellulose and one or more suitable pharmaceutically acceptable excipients; and its process of preparation.
Present invention relates to a thermostable, non-emulsified alcohol free foamable composition comprising clobetasol or pharmaceutically acceptable salt thereof, atleast one C4-C6 glycol, two or more surfactants and/or one or more pharmaceutically acceptable carriers. The non-emulsified alcohol free foamable comp...
Present invention relates to a stable pharmaceutical composition comprising Dapagliflozin and Saxagliptin, wherein Dapagliflozin and Saxagliptin are present in close contact with each other. The pharmaceutical composition of the present invention contains very low impurity and remains stable for a longer period of t...
Present invention relates to a stable bilayer pharmaceutical composition comprising Agomelatine or its pharmaceutically acceptable salts. Invention also relates to process of preparation of said stable bilayer pharmaceutical composition and its use in the treatment of major depressive episodes.
...
Provided herein are novel fused pyrimidinone derivatives of Formula (I) and synthetic intermediates that are useful in preparing the compounds of formula (I). Further provided herein is a method for preparation of a compound of formula (I) or intermediates a pharmaceutical composition comprising a compound of formul...
The present invention relates to an intranasal composition particularly once weekly intranasal composition comprising methylcobalamin and at least one gelling agent and a process for preparation thereof.
The present invention relates to topical pharmaceutical compositions comprising Apremilast in an amount of about 0.1 to 5 % w/w of the total composition and one or more pharmaceutically acceptable excipients and process for their preparation. The present invention further relates to method for treatment of skin dise...
The present invention relates to solid state form of Valbenazine Ditosylate and pharmaceutical composition thereof. Furthermore, the present invention also relates to process for the preparation of Valbenazine Ditosylate.
The present invention is directed to methods of producing substituted pyrazole based compounds through novel intermediates and unique processes for preparing such intermediates which enables synthesis of final product through commercially viable route of synthesis. The present invention is also directed to novel met...
Present invention relates to a new package for moisture-sensitive products, that includes a ring canister with a built in desiccant. The ring canister desiccant container of the present invention suitable or can be fitted with any type of desiccant, so it is for multi-purpose use. This package particularly relates t...
An intranasal composition as unit dosage comprising tapentadol or a pharmaceutically acceptable salt thereof in an amount that is equivalent to about 19.3 mg tapentadol free base; and at least one nasal carrier. After intranasal administration to the human a tapentadol mean Cmax-value achieved by said unit dose is e...
The present invention relates to a bilayer tablet of ticagrelor. More particularly, the present invention relates to a bilayer tablet of ticagrelor for once daily administration comprising immediate release layer and extended release layer that provides the release of ticagrelor upto 24 hrs.
The present invention provides a novel 5-fluoro-1-[(2-fluorophenyl) methyl]-1H-pyrazolo [3, 4-b] pyridine-3-carboximidamide formate compound of formula (IV) and process for preparation thereof. The present invention further provides for the use of compound of formula (IV) for the preparation of vericiguat compound o...
Registered Trademarks
[Class : 5] Pharmaceutical And Medical Preparations, Dietary And Nutritional Supplements, Nutraceuticals Included In Class 5.
[Class : 5] Pharmaceutical And Medical Preparations, Dietary And Nutritional Supplements, Nutraceuticals Included In Class 5.
[Class : 5] Pharmaceutical And Medical Preparations, Dietary And Nutritional Supplements, Nutraceuticals Included In Class 5
View +1980 more Brands for Torrent Pharmaceuticals Ltd.
Charges
12 June 2019
Axis Bank Limited
500 Crore
10 May 2019
Hdfc Bank Limited
250 Crore
28 November 2018
Union Bank Of India
450 Crore
22 November 2018
Director Of Industries Himachal Pradesh
30 Lak
12 October 2018
Idbi Trusteeship Services Limited
1,000 Crore
26 April 2018
Idbi Trusteeship Services Limited
600 Crore
21 August 2017
Idbi Trusteeship Services Limited
302 Crore
10 August 2017
Idbi Trusteeship Services Limited
500 Crore
20 December 2016
Citi Bank N.a.
331 Crore
09 November 2015
Idbi Trusteeship Services Limited
240 Crore
09 November 2015
Idbi Trusteeship Services Limited
250 Crore
20 September 2014
Axis Bank Limited
300 Crore
07 June 2014
Idbi Trusteeship Services Limited
115 Crore
05 April 2013
Bnp Paribas
50 Crore
31 December 2012
The Hongkong And Shanghai Banking Corporation Limited
50 Crore
04 July 2006
Standard Chartered Bank
44 Crore
05 May 2005
Citibank N.a.
50 Crore
11 January 2005
Corporation Bank
450 Crore
29 September 1988
Gujarat Industrial Investment Corporation Ltd.
60 Lak
16 March 1988
State Bank Of Inida
74 Lak
13 August 2013
Hsbc Bank (mauritius) Limited
110 Crore
31 July 2014
Idbi Trusteeship Services Limited
26 Crore
31 July 2014
Idbi Trusteeship Services Limited
276 Crore
19 August 2015
Corporation Bank
300 Crore
05 June 2014
Bnp Paribas
200 Crore
24 April 2015
Bnp Paribas
200 Crore
15 April 2013
The Hongkong And Shanghai Banking Corporation Limited
15 Crore
08 July 2013
The Hongkong And Shanghai Banking Corporation Limited
15 Crore
25 October 2010
Bnp Paribas
85 Crore
17 July 2008
Bnp Paribas
80 Crore
24 January 2007
State Bank Of India
18 Crore
30 November 2011
State Bank Of India
14 Crore
30 September 2004
Standard Chartered Bank
1 Crore
13 January 2005
Industrial Development Bank Of India Limited
60 Crore
01 June 2007
Cooperative Centrale Raiffeisen-boerenleen Bank Ba Singapore Branch
89 Crore
27 March 2006
Export Import Bank Of India
46 Crore
07 March 2006
Export Import Bank Of India
46 Crore
29 April 2005
Citibank N.a.
5 Crore
29 April 2005
Citi Bank N.a.
3 Crore
13 September 2004
Export - Import Bank Of India
50 Crore
13 January 2005
Idbi Bank Ltd.
50 Crore
17 May 2005
Cooperatieve Centrale Raiffeisen - Boerenleenbank B.a.
2 Crore
26 June 1995
Corporation Bank
5 Crore
07 August 1999
Canara Bank
0
05 April 1988
Gujarat State Financial Corporation
60 Lak
28 March 1988
Gujarat Industrial Investment Corporation Ltd.
90 Lak
02 July 1991
Gujarat Industrial Investment Corporation Ltd.
42 Lak
21 January 1988
State Bank Of Idnia
20 Lak
22 May 1992
State Bank Of India
1 Crore
25 March 1991
Bank Of Baroda
1 Crore
19 March 2021
Housing Development Finance Corporation Limited
400 Crore
15 September 2020
Idbi Trusteeship Services Limited
195 Crore
20 August 2020
Idbi Trusteeship Services Limited
200 Crore
06 June 2020
Hdfc Bank Limited
250 Crore
06 June 2020
Hdfc Bank Limited
300 Crore
24 February 2020
Idbi Trusteeship Services Limited
300 Crore
13 March 2018
Idbi Trusteeship Services Limited
10,000 Crore
12 May 2017
Idbi Trusteeship Services Limited
150 Crore
30 May 2023
The Hongkong And Shanghai Banking Corporation Limited
0
10 May 2023
The Hongkong And Shanghai Banking Corporation Limited
0
07 February 2023
Idbi Trusteeship Services Limited
0
24 February 2023
Hdfc Bank Limited
0
13 March 2018
Idbi Trusteeship Services Limited
0
07 June 2014
Idbi Trusteeship Services Limited
0
26 April 2018
Idbi Trusteeship Services Limited
0
12 October 2018
Idbi Trusteeship Services Limited
0
10 May 2019
Hdfc Bank Limited
0
12 June 2019
Axis Bank Limited
0
02 April 2022
Hdfc Bank Limited
0
24 February 2020
Idbi Trusteeship Services Limited
0
19 March 2021
Others
0
12 May 2017
Idbi Trusteeship Services Limited
0
20 August 2020
Idbi Trusteeship Services Limited
0
09 November 2015
Idbi Trusteeship Services Limited
0
17 July 2008
Bnp Paribas
0
15 September 2020
Idbi Trusteeship Services Limited
0
06 June 2020
Hdfc Bank Limited
0
06 June 2020
Hdfc Bank Limited
0
28 November 2018
Others
0
22 November 2018
Others
0
10 August 2017
Idbi Trusteeship Services Limited
0
09 November 2015
Idbi Trusteeship Services Limited
0
13 August 2013
Others
0
30 November 2011
State Bank Of India
0
21 August 2017
Idbi Trusteeship Services Limited
0
20 September 2014
Axis Bank Limited
0
31 July 2014
Idbi Trusteeship Services Limited
0
22 May 1992
State Bank Of India
0
05 April 2013
Bnp Paribas
0
15 April 2013
The Hongkong And Shanghai Banking Corporation Limited
0
31 December 2012
The Hongkong And Shanghai Banking Corporation Limited
0
01 June 2007
Cooperative Centrale Raiffeisen-boerenleen Bank Ba Singapore Branch
0
24 January 2007
State Bank Of India
0
20 December 2016
Citi Bank N.a.
0
08 July 2013
The Hongkong And Shanghai Banking Corporation Limited
0
05 April 1988
Gujarat State Financial Corporation
0
28 March 1988
Gujarat Industrial Investment Corporation Ltd.
0
29 April 2005
Citi Bank N.a.
0
30 September 2004
Standard Chartered Bank
0
17 May 2005
Cooperatieve Centrale Raiffeisen - Boerenleenbank B.a.
0
05 May 2005
Citibank N.a.
0
11 January 2005
Others
0
24 April 2015
Bnp Paribas
0
07 August 1999
Canara Bank
0
31 July 2014
Idbi Trusteeship Services Limited
0
02 July 1991
Gujarat Industrial Investment Corporation Ltd.
0
13 January 2005
Idbi Bank Ltd.
0
21 January 1988
State Bank Of Idnia
0
16 March 1988
State Bank Of Inida
0
26 June 1995
Corporation Bank
0
25 March 1991
Bank Of Baroda
0
29 September 1988
Gujarat Industrial Investment Corporation Ltd.
0
13 January 2005
Industrial Development Bank Of India Limited
0
27 March 2006
Export Import Bank Of India
0
07 March 2006
Export Import Bank Of India
0
04 July 2006
Standard Chartered Bank
0
25 October 2010
Bnp Paribas
0
19 August 2015
Others
0
29 April 2005
Citibank N.a.
0
05 June 2014
Bnp Paribas
0
13 September 2004
Export - Import Bank Of India
0
30 May 2023
The Hongkong And Shanghai Banking Corporation Limited
0
10 May 2023
The Hongkong And Shanghai Banking Corporation Limited
0
07 February 2023
Idbi Trusteeship Services Limited
0
24 February 2023
Hdfc Bank Limited
0
13 March 2018
Idbi Trusteeship Services Limited
0
07 June 2014
Idbi Trusteeship Services Limited
0
26 April 2018
Idbi Trusteeship Services Limited
0
12 October 2018
Idbi Trusteeship Services Limited
0
10 May 2019
Hdfc Bank Limited
0
12 June 2019
Axis Bank Limited
0
02 April 2022
Hdfc Bank Limited
0
24 February 2020
Idbi Trusteeship Services Limited
0
19 March 2021
Others
0
12 May 2017
Idbi Trusteeship Services Limited
0
20 August 2020
Idbi Trusteeship Services Limited
0
09 November 2015
Idbi Trusteeship Services Limited
0
17 July 2008
Bnp Paribas
0
15 September 2020
Idbi Trusteeship Services Limited
0
06 June 2020
Hdfc Bank Limited
0
06 June 2020
Hdfc Bank Limited
0
28 November 2018
Others
0
22 November 2018
Others
0
10 August 2017
Idbi Trusteeship Services Limited
0
09 November 2015
Idbi Trusteeship Services Limited
0
13 August 2013
Others
0
30 November 2011
State Bank Of India
0
21 August 2017
Idbi Trusteeship Services Limited
0
20 September 2014
Axis Bank Limited
0
31 July 2014
Idbi Trusteeship Services Limited
0
22 May 1992
State Bank Of India
0
05 April 2013
Bnp Paribas
0
15 April 2013
The Hongkong And Shanghai Banking Corporation Limited
0
31 December 2012
The Hongkong And Shanghai Banking Corporation Limited
0
01 June 2007
Cooperative Centrale Raiffeisen-boerenleen Bank Ba Singapore Branch
0
24 January 2007
State Bank Of India
0
20 December 2016
Citi Bank N.a.
0
08 July 2013
The Hongkong And Shanghai Banking Corporation Limited
0
05 April 1988
Gujarat State Financial Corporation
0
28 March 1988
Gujarat Industrial Investment Corporation Ltd.
0
29 April 2005
Citi Bank N.a.
0
30 September 2004
Standard Chartered Bank
0
17 May 2005
Cooperatieve Centrale Raiffeisen - Boerenleenbank B.a.
0
05 May 2005
Citibank N.a.
0
11 January 2005
Others
0
24 April 2015
Bnp Paribas
0
07 August 1999
Canara Bank
0
31 July 2014
Idbi Trusteeship Services Limited
0
02 July 1991
Gujarat Industrial Investment Corporation Ltd.
0
13 January 2005
Idbi Bank Ltd.
0
21 January 1988
State Bank Of Idnia
0
16 March 1988
State Bank Of Inida
0
26 June 1995
Corporation Bank
0
25 March 1991
Bank Of Baroda
0
29 September 1988
Gujarat Industrial Investment Corporation Ltd.
0
13 January 2005
Industrial Development Bank Of India Limited
0
27 March 2006
Export Import Bank Of India
0
07 March 2006
Export Import Bank Of India
0
04 July 2006
Standard Chartered Bank
0
25 October 2010
Bnp Paribas
0
19 August 2015
Others
0
29 April 2005
Citibank N.a.
0
05 June 2014
Bnp Paribas
0
13 September 2004
Export - Import Bank Of India
0
30 May 2023
The Hongkong And Shanghai Banking Corporation Limited
0
10 May 2023
The Hongkong And Shanghai Banking Corporation Limited
0
07 February 2023
Idbi Trusteeship Services Limited
0
24 February 2023
Hdfc Bank Limited
0
13 March 2018
Idbi Trusteeship Services Limited
0
07 June 2014
Idbi Trusteeship Services Limited
0
26 April 2018
Idbi Trusteeship Services Limited
0
12 October 2018
Idbi Trusteeship Services Limited
0
10 May 2019
Hdfc Bank Limited
0
12 June 2019
Axis Bank Limited
0
02 April 2022
Hdfc Bank Limited
0
24 February 2020
Idbi Trusteeship Services Limited
0
19 March 2021
Others
0
12 May 2017
Idbi Trusteeship Services Limited
0
20 August 2020
Idbi Trusteeship Services Limited
0
09 November 2015
Idbi Trusteeship Services Limited
0
17 July 2008
Bnp Paribas
0
15 September 2020
Idbi Trusteeship Services Limited
0
06 June 2020
Hdfc Bank Limited
0
06 June 2020
Hdfc Bank Limited
0
28 November 2018
Others
0
22 November 2018
Others
0
10 August 2017
Idbi Trusteeship Services Limited
0
09 November 2015
Idbi Trusteeship Services Limited
0
13 August 2013
Others
0
30 November 2011
State Bank Of India
0
21 August 2017
Idbi Trusteeship Services Limited
0
20 September 2014
Axis Bank Limited
0
31 July 2014
Idbi Trusteeship Services Limited
0
22 May 1992
State Bank Of India
0
05 April 2013
Bnp Paribas
0
15 April 2013
The Hongkong And Shanghai Banking Corporation Limited
0
31 December 2012
The Hongkong And Shanghai Banking Corporation Limited
0
01 June 2007
Cooperative Centrale Raiffeisen-boerenleen Bank Ba Singapore Branch
0
24 January 2007
State Bank Of India
0
20 December 2016
Citi Bank N.a.
0
08 July 2013
The Hongkong And Shanghai Banking Corporation Limited
0
05 April 1988
Gujarat State Financial Corporation
0
28 March 1988
Gujarat Industrial Investment Corporation Ltd.
0
29 April 2005
Citi Bank N.a.
0
30 September 2004
Standard Chartered Bank
0
17 May 2005
Cooperatieve Centrale Raiffeisen - Boerenleenbank B.a.
0
05 May 2005
Citibank N.a.
0
11 January 2005
Others
0
24 April 2015
Bnp Paribas
0
07 August 1999
Canara Bank
0
31 July 2014
Idbi Trusteeship Services Limited
0
02 July 1991
Gujarat Industrial Investment Corporation Ltd.
0
13 January 2005
Idbi Bank Ltd.
0
21 January 1988
State Bank Of Idnia
0
16 March 1988
State Bank Of Inida
0
26 June 1995
Corporation Bank
0
25 March 1991
Bank Of Baroda
0
29 September 1988
Gujarat Industrial Investment Corporation Ltd.
0
13 January 2005
Industrial Development Bank Of India Limited
0
27 March 2006
Export Import Bank Of India
0
07 March 2006
Export Import Bank Of India
0
04 July 2006
Standard Chartered Bank
0
25 October 2010
Bnp Paribas
0
19 August 2015
Others
0
29 April 2005
Citibank N.a.
0
05 June 2014
Bnp Paribas
0
13 September 2004
Export - Import Bank Of India
0
Documents
Form MSME FORM I-23102020_signed
Form CHG-9-17102020-signed
Certificate of registration of charge-20201017
Copy of the resolution authorising the issue of the debenture series.-13102020
Optional Attachment-(1)-13102020
Instrument of creation or modification of charge-13102020
Optional Attachment-(2)-13102020
Optional Attachment-(3)-13102020
Optional Attachment-(3)-08102020
Form DIR-12-08102020_signed
Optional Attachment-(2)-08102020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-08102020
Optional Attachment-(1)-08102020
Shareholders_R63131577_ARCHANA2015_20200929213019.xlsm
Debentureholders_R63131577_ARCHANA2015_20200929213059.xlsm
Certificate of registration of charge-20200929
Form CHG-9-29092020-signed
Form MGT-7-28092020
Optional Attachment-(3)-28092020
Copy of MGT-8-28092020
Optional Attachment-(1)-28092020
Optional Attachment-(2)-28092020
Optional Attachment-(4)-28092020
Optional Attachment-(5)-28092020
Form MGT-6-19092020_signed
-19092020
Instrument of creation or modification of charge-09092020
Optional Attachment-(1)-09092020
Copy of the resolution authorising the issue of the debenture series.-09092020
Optional Attachment-(2)-09092020
